MINT: “Micro et nanomédecines translationnelles”


Team description

Keywords:Nanovectorization, endothelial barrier, vascular endothelium, tumor microenvironment


The MINT laboratory is funded by the University of Angers, as well as the French National Institute of Health and Medical Research (INSERM) and The French National Center for Scientific Research (CNRS). Located within the Hospital Facility, the MINT laboratory consists of 40 researchers and PhD students with expertise in diverse fields including; colloids and inferfaces physio-chemistry; galenic chemistry for pharmaceutical formulation; biological research; and imaging. All our research is focused on the design of nano- and micro-scaled vectors for the delivery of therapeutics (encompassing proteins, anti-cancer drugs, DNA, SiRNA, etc.) and/or imaging probes.


Endothelial cell, during tumorigenesis, is at the crossroads of many metabolic processes explaining its role in the regulation of angiogenesis or endothelial-mesenchymal transition. These two processes help to promote swarming and tumor growth through the development of metastases. All abnormalities, secondary to changes in the biology of endothelial cells, induce irregular blood perfusion, which has the effect of angiogenesis by maintaining hypoxia and acidification of certain areas of the tumor. Thus, the distribution of therapeutic drugs is modified and limited, especially at the tumor level. Therefore, in order to remove endothelial barrier resistance, we propose to develop new strategies: (i) to identify the molecular mechanisms underlying endothelial physiology changes during cancer in order to (ii) propose the formulation of vectors are to target endothelial cells (or differentiated from them) and thus modulating the vascular endothelium.




Pr O. Duval et Dr JJ. Helesbeux (EA 921, Angers) : Ethoxydine et dérivés de delphinidine

Pr B. Lapied et Pr V. Marchais (UPRES EA 2647/USC Inra 1330, Angers) : DEET et angiogenèse

Dr F. Paris (UMR Inserm 892, CNRS 6299) : angiotensine, cancer et radiations ionisantes

Dr I. Corre (UMR Inserm S 1238) : endothélium, cancer et micro-environnement tumoral

Pr O. Herault (UMR CNRS 7292) : métabolisme, différenciation cellulaire



Pr O. Sergent et Dr D. Lagadic (UMR Inserm 1085, Rennes) : toxiques environnementaux

Dr P. Bernard et Dr QT. Do (Greenpharma, Orléans) : Modélisation moléculaire


Internationales :

Pr GJ. Thomas - Cancer Sciences Unit, Faculty of Medicine, University of Southampton (UK) : NOX 4 et micro-environnement tumoral

Pr L. Hein - Institute of Experimental and Clinical Pharmacology and Toxicology, University of Fribourg (Germany) : Récepteurs AT2 et tumorigenèse

Dr GB. Willars - Departement of cell physiology and pharmacology, University of Leicester (UK) : DEET et récepteurs muscariniques M3

Pr R. Widdop - Department of Pharmacology, Monash University, Victoria (Australia): récepteurs AT2

Pr I. Laher - Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver (Canada): angiogenèse, diabète et polyphénols

Place - Find us

Institut de Biologie en Santé – CHU

4, rue Larrey

49933 Angers Cedex